Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1, 2012, Pages 67-76

  Williams Herman, D ^a   Xu, L ^a   Teng, R ^a   Golm, G T ^a   Johnson, J ^a   Davies, M J ^a   Kaufman, K D ^a   Goldstein, B J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DPP IV inhibitor; Metformin; Type 2 diabetes; cell

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ADULT; ARTICLE; CELL FUNCTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 83655163721     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01492.x     Document Type: Article

References (31)

1. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32(Suppl. 3): 35-45.
2. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
3. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
4. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114-1120.
5. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005; 5: 275-286.
6. Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005; 7: 2-8.
7. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
8. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
9. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008; 24: 489-496.
10. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 489-512.
11. Migoya EM, Bergeron R, Miller JL et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801-808.
12. Mannucci E, Ognibene A, Cremasco F et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
13. Migoya E, Miller J, Luo WL et al. Sitagliptin and metformin increase active GLP-1 by complementary mechanisms in treatment-naive patients with type 2 diabetes (abstract). Diabetes 2010; 59(Suppl. 1): A156.
14. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
15. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-583.
16. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-451.
17. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001; 50: 150-158.
18. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
19. Barrett PH, Bell BM, Cobelli C et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998; 47: 484-492.
20. Hodges JL, Lehmann EL. The efficiency of some nonparametric competitors of the t-test. Ann Math Statist 1956; 27: 324-335.
21. Tukey JW. The future of data analysis. Ann Math Statist 1962; 33: 1-67.
22. Campioni M, Toffolo G, Shuster LT, Service FJ, Rizza RA, Cobelli C. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 2007; 292: E54-E60.
23. Xu L, Dalla Man C, Charbonnel B et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10: 1212-1220.
24. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186-193.
25. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-767.
26. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-4058.
27. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
28. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
29. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 1995; 18: 255-260.
30. Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008; 93: 103-109.
31. Seck T, Nauck MA, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.